AU2021275117A1 - Preparation and purification of hypersialylated IgG - Google Patents

Preparation and purification of hypersialylated IgG Download PDF

Info

Publication number
AU2021275117A1
AU2021275117A1 AU2021275117A AU2021275117A AU2021275117A1 AU 2021275117 A1 AU2021275117 A1 AU 2021275117A1 AU 2021275117 A AU2021275117 A AU 2021275117A AU 2021275117 A AU2021275117 A AU 2021275117A AU 2021275117 A1 AU2021275117 A1 AU 2021275117A1
Authority
AU
Australia
Prior art keywords
hsigg
igg antibodies
active portion
igg
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021275117A
Other languages
English (en)
Inventor
Steffen GRAHAM
John Schaeck
Radouane ZOUAOUI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Momenta Pharmaceuticals Inc
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of AU2021275117A1 publication Critical patent/AU2021275117A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Water Supply & Treatment (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2021275117A 2020-05-19 2021-05-19 Preparation and purification of hypersialylated IgG Pending AU2021275117A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063026875P 2020-05-19 2020-05-19
US63/026,875 2020-05-19
PCT/US2021/033156 WO2021236769A1 (en) 2020-05-19 2021-05-19 Preparation and purification of hypersialylated igg

Publications (1)

Publication Number Publication Date
AU2021275117A1 true AU2021275117A1 (en) 2022-12-01

Family

ID=78708028

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021275117A Pending AU2021275117A1 (en) 2020-05-19 2021-05-19 Preparation and purification of hypersialylated IgG

Country Status (11)

Country Link
US (1) US20230193339A1 (https=)
EP (1) EP4153617A4 (https=)
JP (1) JP2023526527A (https=)
KR (1) KR20230012560A (https=)
CN (1) CN115715296A (https=)
AU (1) AU2021275117A1 (https=)
BR (1) BR112022023377A2 (https=)
CA (1) CA3182023A1 (https=)
CO (1) CO2022018364A2 (https=)
MX (1) MX2022014520A (https=)
WO (1) WO2021236769A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022023334A2 (pt) * 2020-05-19 2022-12-20 Momenta Pharmaceuticals Inc Imunoglobulina hipersialilada

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113604A2 (en) * 2004-05-14 2005-12-01 Hematech, Llc Methods for immunoglobulin purification
PH12012502193A1 (en) * 2010-05-06 2021-08-09 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
AU2011290672B2 (en) * 2010-08-20 2015-07-09 Novartis Ag Antibodies for epidermal growth factor receptor 3 (HER3)
EP2877589B1 (en) * 2012-07-26 2024-03-06 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
EP2935610A4 (en) * 2012-12-20 2016-08-31 Medimmune Llc METHODS OF USING ION EXCHANGE CHROMATOGRAPHY TO CONTROL GLYCOFORM RATES WITH HIGH MANNOSIS
WO2014144621A2 (en) * 2013-03-15 2014-09-18 Pyranose Biotherapeutics, Inc. Modified fc fusion proteins
CN104327180A (zh) * 2013-07-23 2015-02-04 天士力制药集团股份有限公司 一种重组人血小板衍生生长因子bb的纯化方法

Also Published As

Publication number Publication date
JP2023526527A (ja) 2023-06-21
CA3182023A1 (en) 2021-11-25
CN115715296A (zh) 2023-02-24
BR112022023377A2 (pt) 2022-12-20
CO2022018364A2 (es) 2022-12-30
EP4153617A1 (en) 2023-03-29
MX2022014520A (es) 2023-03-03
KR20230012560A (ko) 2023-01-26
EP4153617A4 (en) 2024-11-20
US20230193339A1 (en) 2023-06-22
WO2021236769A1 (en) 2021-11-25

Similar Documents

Publication Publication Date Title
EP2729482B1 (en) Method for purifying fc-fusion protein
JP7835691B2 (ja) 高シアル化免疫グロブリン
JP2021519590A (ja) 糖タンパク質の製造
Giddens et al. Chemoenzymatic glyco-engineering of monoclonal antibodies
WO2022038565A1 (en) Hypersialylated immunoglobulin
US20240336946A1 (en) Solid-phase glycan remodeling of glycoproteins
Hsu et al. Successive remodeling of IgG glycans using a solid-phase enzymatic platform
US20230193339A1 (en) Preparation and Purification of Hypersialylated IGG
WO2021178682A2 (en) Methods of making hyper-sialylated immunoglobulin
RU2844159C1 (ru) Получение и очистка гиперсиалилированного igg
US20230303984A1 (en) Enzymes for Sialylation of Glycans
RU2847105C1 (ru) Способы получения гиперсиалилированного иммуноглобулина
RU2849059C1 (ru) Ферменты для сиалилирования гликанов
Pinto Novel capture processes for monoclonal antibodies purification